115 related articles for article (PubMed ID: 8605675)
1. Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma.
Percy AJ; Trainor DA; Rittenhouse J; Phelps J; Koda JE
Clin Chem; 1996 Apr; 42(4):576-85. PubMed ID: 8605675
[TBL] [Abstract][Full Text] [Related]
2. Plasma amylin and insulin concentrations in normoglycemic and hyperglycemic cats.
Lutz TA; Rand JS
Can Vet J; 1996 Jan; 37(1):27-34. PubMed ID: 8746416
[TBL] [Abstract][Full Text] [Related]
3. Deficiency of total and nonglycosylated amylin in plasma characterizes subjects with impaired glucose tolerance and type 2 diabetes.
Mäkimattila S; Fineman MS; Yki-Järvinen H
J Clin Endocrinol Metab; 2000 Aug; 85(8):2822-7. PubMed ID: 10946889
[TBL] [Abstract][Full Text] [Related]
4. Effect of race and hypertension on plasma amylin concentrations.
Dimsdale JE; Kolterman O; Koda J; Nelesen R
Hypertension; 1996 Jun; 27(6):1273-6. PubMed ID: 8641735
[TBL] [Abstract][Full Text] [Related]
5. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans.
Butler PC; Chou J; Carter WB; Wang YN; Bu BH; Chang D; Chang JK; Rizza RA
Diabetes; 1990 Jun; 39(6):752-6. PubMed ID: 2189768
[TBL] [Abstract][Full Text] [Related]
6. Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP alpha) in the fasted, anaesthetized rat.
Young AA; Rink TJ; Wang MW
Life Sci; 1993; 52(21):1717-26. PubMed ID: 8502117
[TBL] [Abstract][Full Text] [Related]
7. Amylin and amylin-amide lack an acute effect on blood glucose and insulin.
Ghatei MA; Datta HK; Zaidi M; Bretherton-Watt D; Wimalawansa SJ; MacIntyre I; Bloom SR
J Endocrinol; 1990 Feb; 124(2):R9-11. PubMed ID: 2179452
[TBL] [Abstract][Full Text] [Related]
8. Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity.
Pieber TR; Roitelman J; Lee Y; Luskey KL; Stein DT
Am J Physiol; 1994 Jul; 267(1 Pt 1):E156-64. PubMed ID: 8048505
[TBL] [Abstract][Full Text] [Related]
9. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI
Arzneimittelforschung; 1999 Apr; 49(4):330-4. PubMed ID: 10337452
[TBL] [Abstract][Full Text] [Related]
10. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes.
Ludvik B; Lell B; Hartter E; Schnack C; Prager R
Diabetes; 1991 Dec; 40(12):1615-9. PubMed ID: 1756902
[TBL] [Abstract][Full Text] [Related]
11. Amylin fasting plasma levels are decreased in patients with osteoporosis.
Bronský J; Průsa R
Osteoporos Int; 2004 Mar; 15(3):243-7. PubMed ID: 14605801
[TBL] [Abstract][Full Text] [Related]
12. In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle.
Frontoni S; Choi SB; Banduch D; Rossetti L
Diabetes; 1991 May; 40(5):568-73. PubMed ID: 2022302
[TBL] [Abstract][Full Text] [Related]
13. The specificity of amylin for the diagnosis of pancreatic adenocarcinoma.
Brand RE; Ding XZ; Young CM; Adrian TE
Int J Gastrointest Cancer; 2002; 31(1-3):123-8. PubMed ID: 12622423
[TBL] [Abstract][Full Text] [Related]
14. High-frequency oscillations in circulating amylin concentrations in healthy humans.
Juhl CB; Pørksen N; Sturis J; Hansen AP; Veldhuis JD; Pincus S; Fineman M; Schmitz O
Am J Physiol Endocrinol Metab; 2000 Mar; 278(3):E484-90. PubMed ID: 10710503
[TBL] [Abstract][Full Text] [Related]
15. Amylin/islet amyloid polypeptide: biochemistry, physiology, patho-physiology.
Castillo MJ; Scheen AJ; Lefèbvre PJ
Diabete Metab; 1995 Feb; 21(1):3-25. PubMed ID: 7781840
[TBL] [Abstract][Full Text] [Related]
16. Effects of ciglitazone on endogenous plasma islet amyloid polypeptide and insulin sensitivity in obese-diabetic viable yellow mice.
Gill AM; Yen TT
Life Sci; 1991; 48(7):703-10. PubMed ID: 1990240
[TBL] [Abstract][Full Text] [Related]
17. Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes.
Knowles NG; Landchild MA; Fujimoto WY; Kahn SE
Diabetes Care; 2002 Feb; 25(2):292-7. PubMed ID: 11815498
[TBL] [Abstract][Full Text] [Related]
18. Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity.
Mather KJ; Paradisi G; Leaming R; Hook G; Steinberg HO; Fineberg N; Hanley R; Baron AD
Diabetes Metab Res Rev; 2002; 18(2):118-26. PubMed ID: 11994903
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
20. Plasma amylin concentrations in fasted and fed rats quantified by a monoclonal immunoenzymometric assay.
Vine W; Blase E; Koda J; Young A
Horm Metab Res; 1998 Sep; 30(9):581-5. PubMed ID: 9808328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
